毛喉鞘蕊花挥发性成分的气相色谱-质谱联用分析

目的 分析植物毛喉鞘蕊花的挥发性成分。方法 用乙醚对药材粗粉进行索氏提取，浓缩得浸膏后用气相色谱-质谱联用（GC-MS）对其成分进行分析。结果和结论 共分离出34个峰，鉴定出23种化合物。主成分为单萜和倍半萜，包括a-蒎烯、石竹烯等。     

肥儿调理液对营养性肥胖大鼠脂质代谢的影响

目的观察肥儿调理液对营养性肥胖大鼠脂质代谢及脂肪重量、细胞形态的影响。方法取幼年大白鼠，连续喂饲高营养饲料6周制备营养性肥胖模型，并于第3周开始给药，4周后，取血测量胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）含量；并取脂肪称重和镜下观察脂肪细胞的个数和直径大小变化。结果63．0g／kg肥儿调理液能明显降低营养性肥胖大鼠脂肪湿重，降低血清TC及TG含量，提高HDL-C含量。组织学观察发现，63．0g／kg肥儿调理液还能明显减小脂肪细胞的直径，对单位视野下脂肪细胞个数有增高趋势。结论肥儿调理液对营养性肥胖大鼠脂质代谢有明显促进作用。     

RP—HPLC测定小承气汤中番泻苷A的含量

目的：建立小承气汤中番泻苷A的HPLC含量测定方法。方法：采用Sinochrom C18柱（250mm×4．6mm），流动相：乙腈：水：冰醋酸（60：35：5），流速：1．0ml／min，检测波长：340nm。结果：番泻苷A在0．2-1．0μg范围内与峰面积呈良好的线性关系，回归方程为Y=124．72X＋6．5（r=-0．9995）。结论：所建立的HPLC方法可用于小承气汤的质量控制。     

整合农村卫生资源的探讨

在提出新型农村卫生服务体系的目标模型的基础上，通过对样本县的调查研究，提出了“以功能为导向优化卫生服务机构布局、以效率为条件整合卫生资源存量”的资源整合逻辑模型。资源的整合有利于促进卫生公平，构建基层卫生服务融医疗、预防、保健等于一体的卫生服务模式和提高卫生资源利用效率。     

关于中药血清药理学方法的再思考

血清的形成与凝血及其相关过程（纤溶与补体系统活化）的蛋白酶级联反应以及血小板和白细胞活化有关，这些过程直接影响血标本的组成，并可能也影响中药成分；但这些过程可用抗凝剂而加以避免。因此，血浆的组成较血清能更好地反映生理、病理状况和吸收进入循环血中药物变化。根据已有报道，药物浓度与反应物质在血浆与血清中可能存在差异，故倡导在中药半体内实验中采用血浆药理学方法。由于不同抗凝剂的作用机制各异，究竟哪一抗凝剂适用于哪类半体内实验，需要进一步开展研究。我们建议在大多数中药半体内实验中，可以采取含药血浆与含药血清平行观察，除非事先对该试验的干扰已有充分了解。     

积雪草提取纯化工艺的研究

目的研究积雪草的提取纯化工艺。方法采用正交试验进行工艺优化,薄层色谱扫描法测定羟基积雪草苷含量。结果提取工艺最佳条件为:水提取2次,第1次加10倍量水提取2h,第2次加8倍量水提取1.5h。纯化工艺最佳条件为壳聚糖用量0.4mL/g,药液浓缩比例1.2:1,絮凝温度70℃。结论本方法可节省原料,缩短工时,降低成本,利于工业化大生产。     

肠炎愈片对大鼠溃疡性结肠炎血清白介素-2、一氧化氮的影响研究

目的观察肠炎愈片对大鼠慢性溃疡性结肠炎血清白介素-2(IL-2)、一氧化氮(NO)的影响。方法用免疫法建立大鼠慢性溃疡性结肠炎模型,将造模后的大鼠随机分为模型组、肠炎愈片高、中、低剂量组、补脾益肠丸组、柳氮磺吡啶组6组,另设正常对照组,共7组。观察肠道形态和组织学改变,采用ELISA法测定血清中IL-2、检测用药后血清NO的含量。结果与模型组比较,肠炎愈片各剂量组血清IL-2含量升高(P<0.05);肠炎愈片高、中剂量组血清NO含量显著低于模型组(P<0.01)。肠炎愈片高、中、低剂量组形态和组织学损伤评分明显下降(P<0.05)。结论肠炎愈片各剂量组治疗UC的机制可能与其恢复提高IL-2水平,从而使Th1/Th2的细胞因子恢复平衡有关;减少NO的生成亦是肠炎愈片治疗UC的作用机制之一。     

大补阴丸对实验性甲亢大鼠胸腺病理改变的影响

目的：观察大补阴丸对实验性甲亢大鼠胸腺病理改变的影响。方法：用左甲状腺素钠（优甲乐）灌服造成大鼠甲亢模型,观察大补阴丸（汤剂）不同剂量内服对大鼠胸腺病理改变的影响。结果：大补阴丸低、中剂量组和西药组胸腺厚度明显增加,细胞数目增多,密度增大,网状细胞散在、成熟,小血管丰富充血,可见胸腺小体,其中大补阴丸高剂量组胸腺组织结构同正常组基本相同。结论：大补阴丸能改善甲亢大鼠胸腺病理改变。     

清热解毒中药免疫调节作用的研究进展

本文从器官组织水平、细胞水平以及分子水平综述了清热解毒中药的免疫调节作用的研究进展,认为清热解毒中药在对抗毒邪、热毒方面有较好的疗效,并提出了对中药的研究应更注重整体的观念。     

Hypercholesterolemia treated with medicinal pad-separated moxibustion: A randomized clinical trial隔药饼灸治疗高胆固醇血症-随机临床试验

ObjectiveTo assess the effect of medicinal pad-separated moxibustion for reducing low-density lipoprotein cholesterol (LDL-C) in the patients with hypercholesterolemia.DesignClinical randomized controlled trial with blinding for outcome assessors and statisticians.SettingDepartment of Acupuncture-Moxibustion and Tuina, Department of Physical examination of the First Affiliated Hospital of Hunan University of Chinese Medicine and three community health centers adjacent to the Hospital and University, from July 2015 to December 2017.Patients60 patients with hypercholesterolemia (elevated LDL-C).InterventionsThe therapeutic lifestyle change (TLC) was provided in both groups.In the experiment group, medicinal pad-separated moxibustion was applied using two groups of acupoints (Group No.1: Jùquē [巨阙CV14], Tiānshū [天枢ST25] and Fēnglóng [丰隆ST40]). Group No.2: Xīnshū [心俞BL15], Gānshū [肝俞BL18] and Píshū [脾俞BL20]) alternatively for 3–5 times a week. In the control group, Simvastatin tablets were administered orally by the patients in accordance with instructions in the medication guides (10 mg/d).Main outcome measuresChange of LDL-C after 12 weeks of treatment compared with the baseline.ResultsAfter 12 weeks of treatment, LDL-C was reduced in both the medicinal pad-separated moxibustion group and the simvastatin group compared with that at baseline (both P < 0.05). The difference on change of LDL-C was not significant between groups (P > 0.05). At week 4 of follow-up, LDL-C was reduced compared with that at baseline in the medicinal pad-moxibustion group (P < 0.05), and the difference on change of LDL-C was significant between groups (P < 0.05). At week 12 of follow-up, the difference on change of LDL-C was not significant when compared with the baseline in each group (both P > 0.05) and between groups (P > 0.05). In comparison with values before treatment, the values of triglyceride (TC) and triacylglycerol(TG) were reduced in both groups (all P < 0.05), while value of high-density lipoprotein cholesterol (HDL-C) was increased in the medicinal pad-separated moxibustion group after 12 weeks of treatment (P < 0.05). The change of TG and HDL-C values were significantly different between groups (both P < 0.05). At week 4 of follow-up, values of TC and TG were lower (both P < 0.05) and HDL-C was higher (P < 0.05) when compared with that at baseline in the medicinal pad-separated moxibustion group; and value of TC was lower and HDL-C higher in the medicinal pad-separated moxibustion group compared with that in the simvastatin group (both P < 0.05). At week 12 of follow-up, compared with that at baseline, all blood lipid outcomes were not significantly different either within (P > 0.05) or between groups (P > 0.05).ConclusionMedicinal pad-separated moxibustion could reduce LDL-C and increase HDL-C in patients with hypercholesterolemia. However, these results need to be further verified by study with large sample size.Trial registrationClinicaltrials.gov NCT02269046.